Countries that eliminate oncho and LF create significant economic benefits that catalyze economic growth. For example, by eliminating oncho and controlling LF, Niger added an estimated USD 2.8 billion to its economy over the last 45 years.
In 2022, the END Fund worked with its partners to provide more than 284 million treatments for neglected tropical diseases.
A Note from Our CEO and Board Chair DEAR END FUND PARTNERS & SUPPORTERS, It is often said that it is easy to overestimate what can be achieved in a year, and underestimate what can be achieved in a decade. This feels particularly appropriate as we celebrate the END Fund’s ten-year anniversary and the magnitude…
For all of us, 2020 was a year like no other: the COVID-19 pandemic, school shutdowns, economic losses, an inflection point in the history of confronting racial injustice, and learning to live, work and be in community in radically different ways. In a year where everything changes, sometimes the most important lesson is to allow…
The END Fund is grateful for all of our investors and partners without whom the success achieved in 2019 and beyond would not be possible. Successful NTD control and elimination efforts are dependent on a broad range of partners working together in concert: health and development NGOs, visionary and committed investors, pharmaceutical companies, and leaders…
We remain grateful for the confidence and trust placed in us, with over 941 donors contributing to the END Fund throughout 2018. Donations came from around the world including Israel, South Korea, Portugal, Russia, India, United Arab Emirates, and Nigeria to name a few, which shows the increase of awareness about the END Fund’s work…
In 2017, the END Fund treated over 97 million people for NTDs. That included 2,915 surgeries, 160 million treatments distributed, and 344,324 health workers trained. All these efforts equated to a value of over $119 million in treatments for NTD patients.
In five years, we’ve successfully reached more than 140 million men, women, and children with over 331 million treatments to prevent and control the five most common NTDs, raised over $75 million dollars, leveraged over $403.3 million worth of generously donated medicines, trained over 740,000 health workers, and provided more than 10,000 surgeries to people…
These past four years have been a period of remarkable growth for the END Fund, in which we have amplified our collective efforts to combat NTDs—from engaging a broader community, to growing our staff, to strengthening our partnerships with Ministries of Health, implementing partners, and the people we serve. Since our inception, the END Fund…
